During the past decade, Charleston Neuroscience Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Charleston Neuroscience Center" #1 collaborator was "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Charleston Neuroscience Center" are "Neovascular Age-Related Macular Degeneration" (1 trials) and "Non-proliferative Diabetic Retinopathy" (1 trials). Many other conditions were trialed in "Charleston Neuroscience Center" in a lesser frequency.

Most popular intervention types in "Charleston Neuroscience Center" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials), "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials), "KSI-301" (1 trials) and "Sham injection" (1 trials). Other intervention names were less common.

The vast majority of trials in "Charleston Neuroscience Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Charleston Neuroscience Center". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Charleston Neuroscience Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Charleston Neuroscience Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".